Systematic reviews and meta-analyses sit at the top of the evidence hierarchy — and they’re brutally laborious, often requiring researchers to screen many thousands of citations against strict criteria. Rayyan (rayyan.ai) exists to tame exactly that stage. It’s an AI-powered, web-based, multi-user platform built specifically for managing the screening phase of a systematic review, and it has become a genuine global standard, trusted by more than a million users across universities and medical research. Originating from peer-reviewed academic work, it carries the kind of methodological credibility that matters when your review has to withstand scrutiny.

Unlike the broad discovery and writing tools elsewhere in this category, Rayyan is unapologetically specialised. It does one demanding job — collaborative screening — and does it exceptionally well.

What Rayyan does

AI-assisted screening (the Predictor)

Rayyan’s signature is its AI Predictor engine. As you manually screen a sample of your papers, the AI learns your inclusion and exclusion patterns and begins ranking the remaining thousands of articles by likely relevance, assigning each a five-star rating. That lets you prioritise the most promising papers first and rapidly set aside clearly ineligible ones — a major time saving on what is otherwise a slog. Independent studies have found it reliable: research comparing Rayyan against human screeners concluded it could safely exclude ineligible records below a low star threshold without dropping studies that should have been included, and reviewers have reported time savings on the order of 40% versus their previous methods.

Blind collaboration

Rigorous systematic reviews require at least two independent reviewers screening separately to avoid bias. Rayyan’s Blind Mode is built for this: multiple reviewers work on the same project with each other’s decisions hidden until the blind is lifted, at which point conflicts are surfaced for resolution. Alongside its title-and-abstract screening assistance, this collaboration model is what reviewers most often cite as Rayyan’s edge over alternatives.

Deduplication, PRISMA and mobile

Pulling citations from PubMed, Embase and Scopus inevitably produces duplicates; Rayyan’s high-accuracy deduplication identifies and merges them automatically. It supports the generation of PRISMA flow diagrams required by high-impact journals, so your screening decisions translate cleanly into the documentation reviewers expect. And a dedicated mobile app for iOS and Android lets you screen titles and abstracts on the go — even offline — turning dead time into progress.

How Rayyan scores

Overall score: 8.0 / 10, the average of the eight categories above.

Rayyan pricing

Rayyan offers a genuinely useful free tier alongside affordable paid plans — pricing has shifted over time, so treat these as a guide.

The free three-review tier makes Rayyan one of the most accessible serious research tools around — many reviewers never need to pay.

Where it falls short

It’s a screening tool, not a whole pipeline

The most important thing to understand is scope. Rayyan focuses on screening and does it brilliantly, but it’s not a complete systematic-review platform. It offers little for the later stages — data extraction, risk-of-bias assessment and synthesis — so you’ll combine it with other tools or manual work to finish a review. Rivals like Covidence cover more phases, and enterprise platforms like DistillerSR run the whole regulated pipeline. Choose Rayyan because screening is where you need help, not as an end-to-end solution.

Niche by nature

Rayyan is a tool for people doing systematic reviews specifically. If you’re doing general background reading or an informal literature review, it’s the wrong fit — the discovery and reading tools elsewhere in this category will serve you far better. Its value is concentrated entirely in rigorous evidence synthesis.

Functional, not flashy

The interface is built for the job rather than for delight — efficient and clear once you know it, but utilitarian. That’s a minor gripe for a tool that earns its keep through reliability, but newcomers should expect a short orientation rather than an instantly intuitive experience.

Pros and cons

Who should use Rayyan?

Rayyan is essential for anyone conducting a systematic review or meta-analysis — research teams, medical and health researchers, postgraduates and evidence-synthesis specialists who need to screen large volumes of citations rigorously and collaboratively. Its free tier makes it accessible to students and small teams, and its credibility makes it safe for work destined for high-impact journals.

For the stages Rayyan doesn’t cover, look elsewhere. Elicit and Iris.ai can help with extraction and synthesis at scale, Consensus assists with finding evidence, and EvidenceHunt brings clinical-evidence monitoring. Rayyan owns the screening stage; pair it accordingly.

Verdict

Rayyan is a model of doing one thing superbly. Its AI Predictor genuinely accelerates the most tedious part of a systematic review, Blind Mode supports the rigorous dual screening that methodology demands, and its deduplication and PRISMA support slot neatly into a proper review workflow. Backed by peer-reviewed validation and over a million users, it has earned its status as the screening standard — and its free tier makes that standard remarkably accessible.

The one thing to keep front of mind is scope: this is a screening specialist, not a full systematic-review pipeline, and the AI assists rather than replaces human judgement. Used for what it’s built for, and combined with extraction and synthesis tools to complete the picture, Rayyan is close to indispensable for serious evidence synthesis. Score: 8.0/10.

Frequently asked questions